NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > QCOVID study identifies vaccinated groups at highest risk hospitalisation and death

QCOVID study identifies vaccinated groups at highest risk hospitalisation and death

25 October 2021 · Listed under COVID-19, Digital Health from Hospital to Home

Researchers from the University of Oxford have identified which vaccinated people are at greatest risk from severe Covid-19 leading to hospitalisation or death, from 14 days after the second dose of vaccination, when substantial immunity should be expected.

Woman after receiving injection from healthcare professional
Image: CDC via Unsplash

The research used the QCovid tool, developed in 2020 with support from the NIHR Oxford Biomedical Research Centre, which directly influenced UK policy in February 2021, adding 1.5 million people in February 2021 to list of those advised to shield.

In a paper published in the British Medical Journal, the research team, led by Prof Julia Hippisley-Cox of the University’s Nuffield Department of Primary Care Health Sciences, showed how they were able to identify groups more at risk of hospitalisation or death from Covid-19.

Using national linked datasets from general practice, national immunisation and SARS-CoV-2 testing, death registry and hospital episode data, The researchers analysed a sample of over 6.9m vaccinated adults, of whom 5.2m had both vaccines doses, which was representative of the UK population as a whole.

This sample included 2,031 COVID-19 deaths and 1,929 COVID-19 related hospital admissions, of which 81 deaths and 71 admissions occurred 14 or more days after the second vaccine dose.

Based on this, the researchers developed cumulative risk scores to calculate people’s risk of hospitalisation or death from Covid-19 following one, or two vaccination doses. These scores take into account factors including age, sex, ethnic group and the background rate of COVID infections, and in particular highlight an elevated risk to:

  • Those who are immunosuppressed as a result of chemotherapy, a recent bone marrow or solid organ transplant, or HIV/AIDS
  • People with neurological disorders, including dementia and Parkinson’s
  • Care home residents, and those with chronic disorders including Down’s Syndrome

Prof Hippisley-Cox said: “The UK was the first place to implement a vaccination programme and has some of the best clinical research data in the world. We have developed this new tool using the QResearch database, to help the NHS identify which patients are at highest risk of serious outcomes despite vaccination for targeted intervention. This new tool can also inform discussions between doctors and patients about the level of risk to aid shared decision making.”

The researchers report that there were relatively few COVID-19 related hospitalisations or deaths in the group who had received the second dose of any vaccine, meaning that the study lacked the statistical power to determine if the groups listed above are more, or less, at risk following a second vaccine dose compared with following the first dose.

Furthermore, they did not distinguish between type of vaccination offered, and acknowledge that their study may have been limited by factors such as exposure, as occupation, for example, is not something that is often recorded in general practice or hospital records.

Aziz Sheikh, Professor of Primary Care Research & Development and Director of the Usher Institute at The University of Edinburgh and a co-author of the paper, said: “This enormous national study of over 5 million people vaccinated with two doses across the UK has found that a small minority of people remain at risk of COVID-19 hospitalisation and death.  Our risk calculator helps to identify those who remain most at risk post-vaccination.

“Our new QCovid tool, developed with the help of experts from across the UK, has been designed to identify those at high risk who may benefit from interventions such as vaccine booster doses or new treatments such as monoclonal antibodies, which can help reduce the risk of progression SARS-CoV-2 infection to serious COVID-19 outcomes.”

The researchers hope that these data can be used in a variety of health and care settings to inform those more likely to be at risk, and potentially help to prioritise those identified for further trials of vaccines, boosters or future preventative therapies.

Prof Hippisley-Cox concluded: “Individual risk will always depend on individual choices as well as the current prevalence of the disease, however we hope that this new tool will help shared decision making and more personalised risk assessment.”

← RECOVERY Trial paper wins BMJ’s Research Paper of the Year Award
Study uncovers gene that doubles risk of death from COVID-19 →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre